The company received gross proceeds of approximately US$1.7 million and net proceeds,
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
AMI to become part of Enpro’s Sealing Technologies Segment
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Sirius JV will be owned 51% by Sirius and 49% by Adani
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Subscribe To Our Newsletter & Stay Updated